PG-11047

PG-11047 is a second-generation polyamine analogue developed for cancer treatment. It acts as a nonfunctional competitor of the natural polyamine spermine, displacing endogenous polyamines from DNA binding sites and interfering with cell cycle processes dependent on polyamines. This disruption leads to inhibition of tumor growth by depleting natural polyamine pools and inducing enzymes involved in polyamine catabolism such as SSAT and SMOX. PG-11047 has demonstrated broad-spectrum anticancer activity in multiple cancer cell lines and animal models, including breast, colon, lung cancers, lymphoma, and advanced refractory solid tumors. It has been studied both as a single agent and in combination with chemotherapeutic agents like cisplatin, erlotinib, 5-fluorouracil (5-FU), bevacizumab, gemcitabine, docetaxel, and sunitinib. Clinical trials have shown it to be well tolerated with manageable toxicity profiles at relatively high doses compared to earlier polyamine analogues[1][2][3][4][5][6].

Other names

PG-11047PG11047PG 11047